M&A
confidence high
sentiment neutral
materiality 0.60
Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M
Immunome Inc.
- Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.
- As of Dec 31, 2022, cash $7.2M, total assets $7.3M, total liabilities $0.8M.
- R&D expense $4.2M in 2022 (2021: $0.5M); G&A $3.3M (2021: $1.6M).
- Merger closed Sep 29, 2023; pro forma combined financials filed as Exhibit 99.3.